scholarly journals Effect of 17β-Estradiol on Somatostatin Receptor Expression and Inhibitory Effects on Growth Hormone and Prolactin Release in Rat Pituitary Cell Cultures

Endocrinology ◽  
1998 ◽  
Vol 139 (5) ◽  
pp. 2272-2277 ◽  
Author(s):  
D. Djordjijevic ◽  
J. Zhang ◽  
M. Priam ◽  
C. Viollet ◽  
D. Gourdji ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Cell Cultures ◽  
Somatostatin Receptor ◽  
Pituitary Cell ◽  
Receptor Expression ◽  
Inhibitory Effects ◽  
Prolactin Release ◽  
Rat Pituitary ◽  
17Β Estradiol

Growth Hormone Regulation in Primary Fetal and Neonatal Rat Pituitary Cell Cultures: The Role of Thyroid Hormone*

Endocrinology ◽  
1991 ◽  
Vol 128 (2) ◽  
pp. 937-943 ◽  
Author(s):  
SHEREEN EZZAT ◽  
DAN LAKS ◽  
JUDY OSTER ◽  
SHLOMO MELMED
Keyword(s):  
Growth Hormone ◽  
Thyroid Hormone ◽  
Cell Cultures ◽  
Pituitary Cell ◽  
Neonatal Rat ◽  
Hormone Regulation ◽  
Rat Pituitary

Comparison of mitogenic activity of (Bu)2cAMP and different growth factors in rat pituitary cell cultures and the influence on hormone secretion

1989 ◽  
Vol 120 (3_Suppl) ◽  
pp. S193
Author(s):  
L. ANGERMÜLLER ◽  
G. K. STALLA ◽  
J. STALLA ◽  
J. MOJTO ◽  
O. A. MÜLLER
Keyword(s):  
Growth Factors ◽  
Cell Cultures ◽  
Hormone Secretion ◽  
Pituitary Cell ◽  
Mitogenic Activity ◽  
Rat Pituitary

A COMPARISON OF THE EFFECTS OF FOUR ERGOT DERIVATIVES ON PROLACTIN SECRETION BY DISPERSED RAT PITUITARY CELLS

1980 ◽  
Vol 87 (1) ◽  
pp. 95-103 ◽  
Author(s):  
G. DELITALA ◽  
T. YEO ◽  
ASHLEY GROSSMAN ◽  
N. R. HATHWAY ◽  
G. M. BESSER
Keyword(s):  
Anterior Pituitary ◽  
Ergot Alkaloids ◽  
Prolactin Secretion ◽  
Pituitary Cells ◽  
Inhibitory Effects ◽  
Prolactin Release ◽  
Ergot Derivatives ◽  
Rat Pituitary ◽  
Rat Pituitary Cells

The inhibitory effects of dopamine and various ergot alkaloids on prolactin secretion were studied using continuously perfused columns of dispersed rat anterior pituitary cells. Bromocriptine (5 nmol/l) and lisuride hydrogen maleate (5 nmol/l) both inhibited prolactin secretion, the effects persisting for more than 3 h after the end of the administration of the drugs. A similar although less long-lasting effect was observed with lergotrile (50 nmol/l) and the new ergoline derivative, pergolide (5 nmol/l). These effects contrasted with the rapid disappearance of the action of dopamine. The potency estimates of the ergots relative to that of dopamine were: lergotrile, 2·3; bromocriptine, 13; lisuride, 15; pergolide, 23. The dopamine-receptor blocking drugs, metoclopramide and haloperidol, antagonized the prolactin release-inhibiting activity of the compounds; bromocriptine and lisuride showed the highest resistance to this dopaminergic blockade. The results suggested that the direct effect of the ergot derivatives on dispersed pituitary cells was mediated through dopamine receptors and emphasized the long-lasting action of bromocriptine and lisuride in vitro.

Correlation between Immunoreactive Growth Hormone and Prolactin Activity in Human and Simian Pituitary Cell Cultures

1969 ◽  
Vol 132 (2) ◽  
pp. 505-508 ◽  
Author(s):  
I. L. Solomon ◽  
D. B. Grant ◽  
I. M. Burr ◽  
S. L. Kaplan ◽  
M. M. Grumbach
Keyword(s):  
Growth Hormone ◽  
Cell Cultures ◽  
Pituitary Cell

Cortical ablation induces time-dependent changes in rat pituitary somatotrophs and upregulates growth hormone receptor expression in the injured cortex

2014 ◽  
Vol 92 (10) ◽  
pp. 1338-1349 ◽  
Author(s):  
Irena Lavrnja ◽  
Vladimir Ajdzanovic ◽  
Svetlana Trifunovic ◽  
Danijela Savic ◽  
Verica Milosevic ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Hormone Receptor ◽  
Growth Hormone Receptor ◽  
Receptor Expression ◽  
Time Dependent ◽  
Cortical Ablation ◽  
Rat Pituitary ◽  
Hormone Receptor Expression

scholarly journals Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro

2005 ◽  
Vol 35 (2) ◽  
pp. 333-341 ◽  
Author(s):  
M C Zatelli ◽  
D Piccin ◽  
F Tagliati ◽  
A Bottoni ◽  
M R Ambrosio ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Primary Culture ◽  
Pituitary Adenomas ◽  
Somatostatin Receptor ◽  
Somatostatin Analogs ◽  
Receptor Subtype ◽  
Inhibitory Effects ◽  
Gh Secretion ◽  
Secretion Inhibition

Dopamine (DA) and somatostatin (SRIF) receptor agonists inhibit growth hormone (GH) secretion by pituitary adenomas. We investigated DA subtype 2 receptor (DR2) and SRIF receptor (sst) subtypes 2 and 5 expression in 25 GH-secreting pituitary adenomas and tested in primary culture the effects on GH and prolactin (PRL) secretion of sst agonists selectively interacting with sst2 (BIM-23120), sst5 (BIM-23206), and sst2 and sst5 (BIM-23244). All adenomas expressed sst2; eight adenomas expressed both sst5 and DR2, eight sst5 but not DR2, and eight DR2 but not sst5. One tissue lacked expression of DR2 and sst5. GH secretion was inhibited by BIM-23120 in all samples, while it was reduced by BIM-23206 only in adenomas not expressing DR2. BIM-23120’s inhibitory effects correlated with sst2 and DR2 expression, whereas DR2 expression correlated inversely with BIM-23206 inhibitory effects on GH secretion. In seven mixed GH-/PRL-secreting pituitary adenomas, PRL secretion was inhibited in sst5-expressing tumors by BIM-23206, but not by BIM-23120. BIM-23244 reduced PRL secretion only in adenomas expressing sst2, sst5 and DR2. sst5 and DR2 expression correlated directly with BIM23206 inhibitory effects on PRL secretion. Our results suggest that adenomas expressing DR2 are less likely to respond to clinically available SRIF analogs in terms of GH secretion inhibition. Therefore, drugs interacting also with DR2 might better control secretion of pituitary adenomas.

Sign in / Sign up

Export Citation Format

Share Document